Topics / Medicinal Products

A subject heading for parliamentary questions

Medicinal Products

1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.

1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked

Questions per month

The record holds no questions for August, when the Dáil does not sit.

Jan 2025Oct 2026
Show as a table
MonthQuestions
January 202517
February 202566
March 202528
April 202535
May 202543
June 202558
July 202556
August 20250
September 202536
October 202538
November 202558
December 202527
January 202618
February 202670
March 2026142
April 202687
May 2026156
June 2026127
July 202682
August 20260
September 202662
October 202627

Who asks, by party

The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.

  • 100% RDR2 from 1 TD · 1 seat today
  • Aontú15 from 2 TDs · 2 seats today
  • Fianna Fáil298 from 31 TDs · 48 seats today
  • Fine Gael171 from 23 TDs · 38 seats today
  • Green Party9 from 1 TD · 1 seat today
  • Independent81 from 11 TDs · 15 seats today
  • Independent Ireland209 from 3 TDs · 4 seats today
  • Labour Party107 from 11 TDs · 11 seats today
  • People Before Profit-Solidarity37 from 3 TDs · 3 seats today
  • Sinn Féin210 from 36 TDs · 39 seats today

The TDs who asked most

Members of the Government answer questions rather than ask them. Each question counts once.

  1. 196
  2. 75
  3. 43
  4. 42
  5. 39
  6. 26
  7. 26
  8. 26

Asked of

Debated under the same heading

Debates whose official heading is exactly these words.

The questions

Aindrias Moynihan Written 22 Oct 2026 · to Health
438. Deputy Aindrias Moynihan asked the Minister for Health the number of times the Health Products Regulatory Authority detected illegal sales of prescription medications; if they were animal or human medications; where they were coming from, in each of the past 12-months, in tabular form; and if she will make a statement on the matter. [75232/26]
Gillian Toole Written 22 Oct 2026 · to Health
465. Deputy Gillian Toole asked the Minister for Health if the HPRA (Health Product Regulatory Authority) warning system will be inspected and upgraded in light of findings from the Food and Drug Administration in the United States where warnings about adverse events relating to Messenger RNA Covid vaccines were not on alerts. [75302/26]
Micheál Carrigy Written 21 Oct 2026 · to Health
188. Deputy Micheál Carrigy asked the Minister for Health the progress on the changing of the reimbursement process for new medicines. [74517/26]
Barry Heneghan Written 21 Oct 2026 · to Health
217. Deputy Barry Heneghan asked the Minister for Health whether the free HRT scheme will be extended to cover hormone replacement therapy for patients with congenital or permanent endocrine conditions, including testosterone replacement for Klinefelter syndrome. [74737/26]
Barry Heneghan Written 21 Oct 2026 · to Health
218. Deputy Barry Heneghan asked the Minister for Health the current status of the HSE's assessment of dupilumab for eosinophilic oesophagitis; and the expected date of a decision. [74736/26]
Barry Heneghan Written 21 Oct 2026 · to Health
219. Deputy Barry Heneghan asked the Minister for Health the action the HSE and HPRA are taking on the current supply shortage of budesonide orodispersible tablets in the State. [74735/26]
Barry Heneghan Written 21 Oct 2026 · to Health
220. Deputy Barry Heneghan asked the Minister for Health the current status of the HSE's full health technology assessment of budesonide orodispersible tablets (Jorveza, NCPE HTA ID 24014) for eosinophilic oesophagitis, commissioned on 25 June 2024; the reason no outcome has been published in over two years; and the expected date of a reimbursement decision. [74734/26]
Eoin Hayes Written 21 Oct 2026 · to Health
248. Deputy Eoin Hayes asked the Minister for Health if her Department will review the eligibility criteria for approved preventative medication for hereditary angioedema (HAE). [74913/26]
Conor D. McGuinness Written 20 Oct 2026 · to Health
893. Deputy Conor D. McGuinness asked the Minister for Health if the assessment and approval process for belzutifan will be expedited (details supplied). [73594/26]
Pádraig Rice Written 20 Oct 2026 · to Health
1018. Deputy Pádraig Rice asked the Minister for Health the current status of a pricing and reimbursement application (details supplied); and the expected date of a decision. [74469/26]
Pádraig Rice Written 20 Oct 2026 · to Health
1021. Deputy Pádraig Rice asked the Minister for Health the actions the HSE and Health Products Regulatory Authority are taking regarding a current supply shortage (details supplied). [74468/26]
Pádraig Rice Written 20 Oct 2026 · to Health
1023. Deputy Pádraig Rice asked the Minister for Health the current status of a full health technology assessment (details supplied); the reason no outcome has been published in over two years; and the expected date for a reimbursement decision. [74466/26]
David Cullinane Written 13 Oct 2026 · to Health
739. Deputy David Cullinane asked the Minister for Health the steps she has taken to ensure that eligible patients will have access to a medication (details supplied) since its approval for reimbursement without avoidable capacity delays; whether regional services will be developed to assist in access and ongoing care; if she will outline the way in which patients will be identified and assessed; the way prescription…
Barry Heneghan Written 13 Oct 2026 · to Health
791. Deputy Barry Heneghan asked the Minister for Health whether she is aware of delays in accessing a drug (details supplied) for Friedreich’s ataxia due to capacity constraints at the Combined Ataxia Clinic, Tallaght University Hospital; the timeframe for all eligible patients to commence treatment; whether additional resources will be provided; the current clinic waiting times; and measures to ensure timely specia…
Peadar Tóibín Written 6 Oct 2026 · to Health
580. Deputy Peadar Tóibín asked the Minister for Health if she is aware that the European Commission granted marketing authorisation on 15 July 2026 for jascayd (nerandomilast); if an application for reimbursement has been received by the HSE and/or the National Centre for Pharmacoeconomics (NCPE); the current status of any assessment, pricing negotiations or reimbursement consideration; the anticipated timeline for …
Michael Cahill Written 6 Oct 2026 · to Health
616. Deputy Michael Cahill asked the Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the combined ataxia clinic at Tallaght University Hospital; the estimated timeframe within which all eligible patients will have commenced tre…
Pádraig Mac Lochlainn Written 6 Oct 2026 · to Health
618. Deputy Pádraig Mac Lochlainn asked the Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the Combined Ataxia Clinic at Tallaght University Hospital; the estimated timeframe within which all eligible patients will have commen…
Louis O'Hara Written 6 Oct 2026 · to Health
626. Deputy Louis O'Hara asked the Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the combined ataxia clinic at Tallaght University Hospital; the estimated timeframe within which all eligible patients will have commenced treat…
Pádraig O'Sullivan Written 6 Oct 2026 · to Health
627. Deputy Pádraig O'Sullivan asked the Minister for Health if a company (details supplied) has engaged with her Department, the HSE or the national centre for pharmacoeconomics regarding reimbursement of ojemda (tovorafenib) in Ireland; whether a reimbursement application has been submitted by the company; if so, the status of that application; if not, whether discussions have taken place with the company regarding…
Eoghan Kenny Written 6 Oct 2026 · to Health
643. Deputy Eoghan Kenny asked the Minister for Health if her Department will consider the inclusion of GLP-1 drugs like Mounjaro for PCOS treatment in the drugs payment scheme, given the expense of the medication and the considerable cost of living issues. [70234/26]
Conor D. McGuinness Written 6 Oct 2026 · to Health
669. Deputy Conor D. McGuinness asked the Minister for Health whether she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing a drug (details supplied) despite its reimbursement from 1 October 2026 due to capacity constraints at the Combined Ataxia Clinic at Tallaght University Hospital; the estimated timeframe within which all eligible patients will have com…
Shay Brennan Written 6 Oct 2026 · to Health
672. Deputy Shay Brennan asked the Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 (details supplied); the estimated timeframe within which all eligible patients will have commenced treatment; if additional resources will be provided to support treatment ini…
Brian Brennan Written 6 Oct 2026 · to Health
675. Deputy Brian Brennan asked the Minister for Health if she will review the fairness of the drug payment scheme threshold, particularly the application of the same monthly cap to widowed/single-person households and to couples or families. [70527/26]
Mary Lou McDonald Written 6 Oct 2026 · to Health
682. Deputy Mary Lou McDonald asked the Minister for Health if there are plans to trial the use of a medication (details supplied) in Ireland in view of the fact his drug is currently being tested in the United States of America for use in preserving fertility for endometriosis patients. [70557/26]
Seán Kyne Written 6 Oct 2026 · to Health
720. Deputy Seán Kyne asked the Minister for Health the current status of the HSE's assessment of dupilumab for eosinophilic oesophagitis; and the expected date of a decision on the use of this medicine. [70680/26]